Back to search
FDAFDA · Food and drugs·Recall number D-0144-2024

SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM Huningue S.A.S., Huningue, France, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936. NDC 0078-0110-22

Published December 13, 2023 · Recall initiated: November 22, 2023

Summary

FDA records drug Class I recall D-0144-2024, published December 13, 2023 and initiated November 22, 2023. Recalling firm: Novartis Pharmaceuticals Corporation; Status: Ongoing; Reported quantity: 6,997 bottles; Lot: Lot #: FX001500, FX001582, Exp. 09/30/2024. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Novartis Pharmaceuticals Corporation
Distributor
Nationwide within the United States
Lot
Lot #: FX001500, FX001582, Exp. 09/30/2024
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM Huningue S.A.S., Huningue, France, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936. NDC 0078-0110-22 recalled?

Yes. FDA published recall D-0144-2024 on December 13, 2023. Reported hazard: Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals

What should I do if I have this product?

Voluntary: Firm initiated · Letter